| Autor: |
Lotfollahzadeh, Saran, Lo, Dominic, York, Emily A., Napoleon, Marc Arthur, Yin, Wenqing, Elzinad, Nagla, Le, John, Zhang, Mengwei, Yang, Xiaosheng, Morrissey, Austin, Elsadawi, Murad, Zhao, Qing, Schaus, Scott E., Hansen, Ulla, Chitalia, Vipul C. |
| Zdroj: |
American Journal of Pathology; 20220101, Issue: Preprints |
| Abstrakt: |
Aberrant hyperactivation of Wnt signaling driven by nuclear β-catenin in the colonic epithelium represents the seminal event in the initiation and progression of colorectal cancer (CRC). Despite its established role in CRC tumorigenesis, clinical translation of Wnt inhibitors remains unsuccessful. LSF (encoded by TFCP2) is a transcription factor and a potent oncogene. We identified a chemotype named Factor Quinolinone Inhibitors (FQIs) that specifically inhibits LSF DNA-binding, partner protein-binding, and transactivation activities. We examined the role of LSF and FQIs in CRC tumor growth. Here, we show that LSF and β-catenin interacted in several CRC cell lines irrespective of their mutational profile, which were disrupted by FQI2-34. FQI2-34 suppressed Wnt activity in CRC cells in a dose-dependent manner. Leveraging both allogeneic and syngeneic xenograft models, we show that FQI2-34 suppressed CRC tumor growth, significantly reduced nuclear β-catenin, and downregulated Wnt targets such as AXIN-2 and SOX-9 in the xenograft cells. FQI2-34 suppressed the proliferation of xenograft cells. Adenocarcinomas from a series of stage IV CRC patients revealed a positive correlation between LSF expression and Wnt targets (AXIN-2 and SOX-9) within the CRC cells. Collectively, this study uncovers the Wnt inhibitory and CRC growth-suppressive effects of these LSF inhibitors in CRC cells, revealing a novel target in CRC therapeutics. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
